GlassScriptPhysician profile
Mohammad Jurri
NPI 1467089078
$1,465.75
in general payments reported to CMS, 2019-2025
21 companies · $579 in 2025
The $579 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $30.99 · 2023: $99.44 · 2024: $757 · 2025: $579.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,435.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,434.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intra-Sana Laboratories | $266.35 | 2024-2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Astrazeneca Pharmaceuticals LP | $230.86 | 2024-2025 | Breztri, Farxiga |
| Novo Nordisk INC | $209.67 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $195.05 | 2023-2025 | Xifaxan, Trulance |
| Lilly USA, LLC | $108.62 | 2022-2025 | Jardiance, Zepbound, Mounjaro |
| Pfizer INC. | $68.33 | 2024-2025 | |
| Optinose US, INC. | $51.82 | 2025 | |
| Currax Pharmaceuticals LLC | $51.19 | 2023-2024 | Contrave |
| Exact Sciences Corporation | $44.66 | 2023-2025 | Cologuard Collection Kit |
| Gilead Sciences, INC. | $35.21 | 2025 | |
| Paratek Pharmaceuticals, INC. | $31.36 | 2024 | Nuzyra |
| Azurity Pharmaceuticals, INC. | $29.11 | 2025 | Azmiro |
| Echosens North America, INC. | $18.72 | 2025 | Fibroscan |
| Tris Pharma INC | $17.99 | 2025 | Dyanavel Xr |
| Cleerly, INC. | $17.40 | 2025 | Cleerly Ischemia, Cleerly Labs |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $15.74 | 2024 | Voquezna |
| Axsome Therapeutics, INC. | $15.37 | 2025 | Auvelity |
| Biogen, INC. | $15.06 | 2025 | Skyclarys |
| Merck Sharp & Dohme LLC | $14.88 | 2024 | Gardasil, Vaxelis, Gardasil 9 |
| Ultragenyx Pharmaceutical INC. | $14.79 | 2022 | |
| Xeris Pharmaceuticals, INC. | $13.57 | 2024 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Jurri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.